Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants

被引：0
|
作者：
Romain Sechaud
Helen Gu
Gholamreza Rahmanzadeh
Amanda Taylor
Ovidiu Chiparus
Gopal Krishna Sharma
Astrid Breitschaft
Hans D. Menssen
机构：
[1] Novartis Pharma AG,
[2] Novartis Pharmaceuticals Corporation,undefined
[3] Novartis Healthcare Pvt. Ltd.,undefined
[4] Parexel International GmbH,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2024年 / 93卷
关键词：
Midostaurin; Drug–drug interaction; Midazolam; Bupropion; Pioglitazone; Oral contraceptive;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：439 / 453
页数：14
相关论文
共 50 条
  • [1] Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants
    Sechaud, Romain
    Gu, Helen
    Rahmanzadeh, Gholamreza
    Taylor, Amanda
    Chiparus, Ovidiu
    Sharma, Gopal Krishna
    Breitschaft, Astrid
    Menssen, Hans D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (05) : 439 - 453
  • [2] Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants (25 Jan, 10.1007/s00280-023-04635-3, 2024)
    Sechaud, Romain
    Gu, Helen
    Rahmanzadeh, Gholamreza
    Taylor, Amanda
    Chiparus, Ovidiu
    Sharma, Gopal Krishna
    Breitschaft, Astrid
    Menssen, Hans D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 487 - 487
  • [3] Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant
    Landry, Ishani
    Aluri, Jagadeesh
    Nakai, Kenya
    Hall, Nancy
    Miyajima, Yukiko
    Ueno, Takashi
    Dayal, Satish
    Filippov, Gleb
    Lalovic, Bojan
    Moline, Margaret
    Reyderman, Larisa
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2021, 10 (06): : 681 - 690
  • [4] Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
    de Jong, Jan
    Mitselos, Anna
    Jurczak, Wojciech
    Cordoba, Raul
    Panizo, Carlos
    Wrobel, Tomasz
    Dlugosz-Danecka, Monika
    Jiao, James
    Sukbuntherng, Juthamas
    Ouellet, Daniele
    Hellemans, Peter
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (05):
  • [5] The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting
    O'Donnell, Charles J.
    Grime, Ken
    Courtney, Paul
    Slee, Dean
    Riley, Robert J.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (03) : 381 - 385
  • [6] A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6
    Di Paolo, Veronica
    Ferrari, Francesco Maria
    Veronese, Davide
    Poggesi, Italo
    Quintieri, Luigi
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2024, 127
  • [7] Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors
    Cannady, Ellen A.
    Wang, Ming-Dauh
    Friedrich, Stuart
    Rehmel, Jessica L. F.
    Yi, Ping
    Small, David S.
    Zhang, Wei
    Suico, Jeffrey G.
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2015, 3 (05):
  • [8] Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
    Loer, Helena Leonie Hanae
    Tuerk, Denise
    Gomez-Mantilla, Jose David
    Selzer, Dominik
    Lehr, Thorsten
    PHARMACEUTICS, 2022, 14 (05)
  • [9] Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil
    Katsumi Iga
    Akiko Kiriyama
    Clinical Pharmacokinetics, 2024, 63 : 43 - 56
  • [10] MILK THISTLE HERB-DRUG INTERACTION STUDY: NO EFFECT ON CYP3A, CYP2C9, AND CYP2D6 ACTIVITIES IN HEALTHY PARTICIPANTS
    Suzuki-Kawaguchi, M.
    Frye, R. F.
    Markowitz, J. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S110 - S110
12345